Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials
Crossref DOI link: https://doi.org/10.1007/s13340-016-0283-x
Published Online: 2016-09-09
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kashiwagi, Atsunori
Yoshida, Satoshi
Kawamuki, Kosei
Nakamura, Ichiro
Kazuta, Kenichi
Ueyama, Eiji
Takahashi, Hideyuki
Akiyama, Noriko
Kondo, Yoshinori
Ogihara, Toshio
Funding for this research was provided by:
Astellas Pharma
License valid from 2016-09-09